Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
On Friday, the European Medicines Agency (EMA) warned patients using weight-loss drugs, such as Novo Nordisk A/S's (NYSE:NVO) Wegovy, to inform their doctors before general anesthesia or deep sedation surgery.
歐洲藥品管理局（EMA）週五警告服用減肥藥物（例如諾和諾德A / S（NYSE：NVO）的Wegovy）的患者，在進行全身麻醉或深度鎮靜手術之前告知醫生。
This recommendation stems from potential respiratory complications linked to these medications.
這項建議源於與這些藥物相關的呼吸併發症的潛在風險。
Related: Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient.
相關:研究顯示，只有25%的患者在服用了諾和諾德公司的維戈維或歐秦匹克兩年後繼續使用；公司稱數據不足。
Weight-loss drugs like Wegovy and Eli Lilly And Co's (NYSE:LLY) Zepbound and Mounjaro belong to a class known as GLP-1 receptor agonists, which slow the emptying of food from the stomach, making users feel full for longer periods.
Wegovy和禮來（Eli Lilly And Co）的Zepbound和Mounjaro等減肥藥屬於叫做GLP-1受體激動劑的藥物類別，減緩胃部排空，使用戶感覺更長時間的飽。
Their action of slowing gastric emptying is already noted in the product information for various drugs in this class, such as dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide.
它們減緩胃的排空作用在該類藥物的各種藥品信息中已經得到注意，例如dulaglutide，exenatide，liraglutide，lixisenatide，semaglutide和tirzepatide。
The EMA's drug safety committee, PRAC, highlighted the risk of aspiration, a condition where stomach contents might move into the respiratory tract, potentially causing pneumonia.
EMA的藥品安全委員會PRAC強調了吸入風險問題，即胃內容物可能移入呼吸道，從而可能導致肺炎。
This risk is particularly concerning for patients undergoing anesthesia or deep sedation during surgery. Although the regulator has not established a definitive causal link between GLP-1 drugs and aspiration, the nature of these medications' action on delaying gastric emptying presents a plausible risk.
對於在手術過程中接受麻醉或深度鎮靜的患者，這種風險特別令人擔憂。儘管監管機構尚未確定GLP-1藥物和吸入性風險之間的確切因果關係，但這些藥物通過延遲胃排空的作用，可能存在一種合理的風險。
The PRAC reviewed data from various sources, including case reports from EudraVigilance, scientific literature, and clinical trials. Despite the inability to confirm a direct association between GLP-1 analogs and aspiration, the committee emphasized the importance of awareness among healthcare professionals and patients regarding the potential risks.
PRAC從EudraVigilance的病例報告，科學文獻和臨床試驗等各種來源中審核了數據。儘管無法確認GLP-1類似物與吸入之間的直接關聯，但委員會強調了醫療保健專業人員和患者對潛在風險的重視。
Aspiration and pneumonia aspiration complicate between one in 900 to one in 10,000 general anesthesia procedures, depending on risk factors.
吸入性和肺炎性吸入併發症發生在每900到10,000次全身麻醉手術中間，這取決於風險因素。
Price Action: NVO shares are up 2.02% at $142.62, and LLY shares are up 0.97% at $943.24 at the last check on Friday.
截至週五最後一次檢查，NVO股票上漲2.02％至142.62美元，LLY股票上漲0.97％至943.24美元。
- Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds.
- 研究發現，諾和諾德的“奇蹟”減肥藥物Ozempic與48％的較低癡呆症風險相關。
Photo by Ciara Kimsey via Shutterstock
照片來自Shutterstock
譯文內容由第三人軟體翻譯。